Astellas mulls options after Gilead's CV offer
This article was originally published in Scrip
Executive Summary
The battle for CV Therapeutics may well not be over. Although Astellas had made no announcement by the end of Tokyo trading on March 13th, there was speculation that the Japanese firm could raise its bid for the US firm in the wake of Gilead Sciences' $1.4 billion white knight offer.